Dyslipidemic drugs in metabolic syndrome

Dyslipidemic drugs in metabolic syndrome

Introduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Statins reduce cardiovascular events, so all metabolic syndrome patients should be evaluated for dyslipidemia. Many patients fail to achieve lipid goals with statin monotherapy. Co-administration of ezetim...

Full description

Bibliographic Details
Main Authors: Sheelu S Siddiqi, Misbahuddin, Farida Ahmad, Syed Z Rahman, Asad U Khan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
3-hydroxy-3-methyglutaryl-CoA
reductase
insulin resistance syndrome
low-density lipoproteincholesterol
statins
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=472;epage=479;aulast=Siddiqi

Internet

http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=472;epage=479;aulast=Siddiqi

Similar Items